TIL (Instil Bio, Inc. Common Stock) Stock Analysis - News
Instil Bio, Inc. Common Stock (TIL) is a publicly traded Healthcare sector company. As of May 21, 2026, TIL trades at $8.02 with a market cap of $55.14M and a P/E ratio of -0.76. TIL moved +1.25% today. Year to date, TIL is -34.74%; over the trailing twelve months it is -51.22%. Its 52-week range spans $5.67 to $70.16. Rallies surfaces TIL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in TIL news today?
Instil Bio Cuts Q1 R&D Spend 87%, Secures $74.7M Cash Runway Through 2027: Instil Bio ended Q1 2026 with $74.7 million in cash, cash equivalents and marketable securities, forecasting funding through 2027. Net loss per share narrowed to $0.62 GAAP and $0.32 non-GAAP, while R&D expenses fell to $0.7 million and G&A to $5.3 million year-over-year.
Laumas Sandeep sold 17.54K (~$404.10K) on Sep 10, 2025.
Laumas Sandeep sold 12.46K (~$297.57K) on Sep 10, 2025.
Vivo Capital IX, LLC bought 300.00K (~$6.00M) on Mar 23, 2021.
TIL Analyst Consensus
TIL analyst coverage data. Average price target: $0.00.
Common questions about TIL
What changed in TIL news today?
Instil Bio Cuts Q1 R&D Spend 87%, Secures $74.7M Cash Runway Through 2027: Instil Bio ended Q1 2026 with $74.7 million in cash, cash equivalents and marketable securities, forecasting funding through 2027. Net loss per share narrowed to $0.62 GAAP and $0.32 non-GAAP, while R&D expenses fell to $0.7 million and G&A to $5.3 million year-over-year.
Does Rallies summarize TIL news?
Yes. Rallies summarizes TIL news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is TIL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TIL. It does not provide personalized investment advice.
